Research programme: respiratory syncytial virus therapeutics - ZymeTxAlternative Names: RSV therapeutics - ZymeTx
Latest Information Update: 16 Jul 2016
At a glance
- Originator ZymeTx
- Class Small molecules
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in USA (PO)
- 11 Mar 2008 Preclinical trials in Respiratory syncytial virus infections in USA (PO)